𝛼SK or SearchQ1 Follow-Up: D. Western Therapeutics Institute (DWTI) (4576 JP) - May 26, 2026
SUMMARY
- In Q1 FY2026/12, D. Western Therapeutics Institute, Inc. (DWTI, hereinafter“the Company”) reported net sales of JPY 15 mn (-84.4% YoY).
- In terms of costs, the Company posted SG&A expenses of JPY 182 mn (-20.2% YoY), including R&D expenses of JPY 117 mn (-17.5% YoY).
- As a result, the Company recorded an operating loss of JPY 167 mn (loss of JPY 142 mn a year earlier), an ordinary loss of JPY 170 mn (loss of JPY 149 mn), and net loss attributable to owners of parent of JPY 170 mn (loss of JPY 150 mn).
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Q1 Follow-Up: D. Western Therapeutics Institute (DWTI) (4576 JP) - May 26, 202605 Jun 2026
x